Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822423 | 0.91 | DPP4 (0.40) | DPP4EDNRBEDNRACNR2CNR1 | |
| SCHEMBL3818189 | 0.88 | KDM1A (0.41) | DPP4CNR1ALDH1A1 | |
| SCHEMBL3820776 | 0.75 | BCL2L1 (0.41) | MCL1ALDH1A1 | |
| SCHEMBL3817260 | 0.75 | CNR1 (0.43) | DPP4EDNRBEDNRACNR1ALDH1A1 | |
| SCHEMBL3821670 | 0.75 | DPP4 (0.46) | DPP4CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL3819328 | 0.74 | DPP4 (0.46) | DPP4CNR2CNR1 | |
| SCHEMBL3819682 | 0.73 | KMT2A (0.41) | DPP4HSD11B1CNR2CNR1 | |
| SCHEMBL3813884 | 0.72 | KDM1A (0.42) | DPP4CNR1 | |
| SCHEMBL3817571 | 0.71 | KMT2A (0.42) | DPP4HSD11B1CNR1 | |
| SCHEMBL3813863 | 0.70 | MEN1 (0.50) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937672-B1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | claimed |
| US-7541361-B2 | N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-02 | — | — | US | claimed |
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | claimed |
| EP-1937672-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2007006928-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | claimed |
| EP-1937672-B1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-7541361-B2 | N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-02 | — | — | US | disclosed |
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1937672-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007006928-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176867-A1 | N-[(4,5-DIPHENYLPYRIMIDIN-2-YL)METHYL]AMINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR THERAPEUTIC USE | NQO1, PRMT5, QDPR | DPP4 1069/4885ALOX5AP 1748/4885FEN1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.